drugset / Trial / NCT02139397
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Phase 1/2
Completed
16 enrolled
Giselle Sholler
Beat NB Cancer Foundation · collabBecause of Ezra · collabK C Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate an investigational drug (DFMO) in combination with bortezomib, for relapsed and refractory neuroblastoma. DFMO is an investigational drug because it has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the safety and tolerability of DFMO in combination with bortezomib as well as the tumors response to this study drug.
Timeline
- Start
- 2014-06-06
- Primary completion
- 2024-01-19
- Completion
- 2024-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |
| Subject | Eflornithine | Small molecule | — | Oral |